TRU
vs
S
S&P/ASX 300
TRU
Over the past 12 months, TRU has underperformed S&P/ASX 300, delivering a return of -46% compared to the S&P/ASX 300's +12% growth.
Stocks Performance
TRU vs S&P/ASX 300
Performance Gap
TRU vs S&P/ASX 300
Performance By Year
TRU vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Truscreen Group Ltd
Glance View
TruScreen Group Ltd. engages in the development, manufacture, and sale of cancer detection device and systems. The firm is engaged in the business of the development, manufacturing and sale of cancer detection devices and systems. Its cervical cancer screening device offers technology in cervical screening, providing detection of precancerous and cancerous cervical cells to help improve the health and well-being of women worldwide. Its real-time cervical cancer technology utilizes a digital wand, which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated algorithm framework is utilized to detect pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue. The product offers an approach to cervical screening, resolving ongoing issues with Pap smear (Pap tests), including failed samples, patient follow-up, patient discomfort and the need for supporting laboratory infrastructure.
